1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Regeneron Releases New Linvoseltamab Analysis As It Inches Toward ASH, Regulatory Filing

 
• By Alaric DeArment

The BCMAxCD3-directed bispecific for multiple myeloma is one of the crown jewels of Regeneron’s larger program to develop bispecifics as it diversifies beyond its traditional core franchises.

Regeneron announced an analysis from the Phase I/II LINKER-MM1 trial of linvoseltamab • Source: Shutterstock

On the eve of the American Society of Hematology annual meeting, Regeneron Pharmaceuticals, Inc. released data on its multiple myeloma drug candidate linvoseltamab that should support its submission to the US Food and Drug Administration this year. Linvoseltamab isn’t getting top billing among Regeneron’s presentations at ASH, but the Tarrytown, NY-based company will present additional data that will support the drug’s profile in a competitive class.

Regeneron released 7 December an analysis of the pivotal Phase I/II LINKER-MM1 trial that showed a 71% objective response rate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

More from Anticancer